SCHEMBL10065870

SCHEMBL10065870

Cc1ccc(CN(C)CCN(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYCR1 P32322 2/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.51
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ TNNI3 P19429 1/20 0.48
▸ TNNT2 P45379 1/20 0.48
▸ TNNC1 P63316 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ BCHE P06276 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ LTA4H P09960 1/20 0.44
▸ CARM1 Q86X55 1/20 0.44
▸ PRMT6 Q96LA8 1/20 0.44
▸ PRMT8 Q9NR22 1/20 0.44
▸ HRH3 Q9Y5N1 4/20 0.43
▸ SIGMAR1 Q99720 2/20 0.42
▸ TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18516614 0.88 PYCR1 (0.52) PYCR1NPSR1MEN1KMT2AALDH1A1
SCHEMBL16312619 0.84 PYCR1 (0.65) PYCR1NPSR1MEN1KMT2AALDH1A1
SCHEMBL10083411 0.83 ALDH1A1 (0.52) PYCR1NPSR1MEN1KMT2ATNNI3
SCHEMBL5028754 0.81 PYCR1 (0.53) PYCR1NPSR1MEN1KMT2AALDH1A1
SCHEMBL22537476 0.81 PYCR1 (0.53) PYCR1NPSR1ALDH1A1KDM4ECARM1
SCHEMBL10051134 0.81 CARM1 (0.68) PYCR1NPSR1ALDH1A1KDM4ECARM1
SCHEMBL3153586 0.81 MAPT (0.48) PYCR1NPSR1MEN1KMT2ATNNI3
SCHEMBL14373882 0.81 PYCR1 (0.53) PYCR1NPSR1MEN1KMT2AALDH1A1
SCHEMBL13889677 0.81 TAAR1 (0.61) PYCR1NPSR1MEN1KMT2ATNNI3
SCHEMBL8221303 0.80 CARM1 (0.67) PYCR1NPSR1MEN1KMT2ATNNI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2117531-B1 COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2016-11-02 — — EP disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 — — US disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 — — US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 — — US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 — — US disclosed
EP-1874305-B1 SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2014-08-27 — — EP disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 — — US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 — — US disclosed
US-8658659-B2 Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE (FR) 2014-02-25 — — US disclosed
US-8450302-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2013-05-28 — — US disclosed
EP-1857459-A2 Pyrazolopyrimidine compound and a process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 2007-11-21 — — EP disclosed
US-20070249628-A1 Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons MOUSSY ALAIN 2007-10-25 — — US disclosed
US-20070249628-A1 Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons MOUSSY ALAIN 2007-10-25 — — US disclosed
EP-1525200-B1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2007-10-10 — — EP disclosed
US-20070225293-A1 Use of C-Kit Inhibitors for Treating Fibrosis AB SCIENCE 2007-09-27 — — US disclosed
US-20070225293-A1 Use of C-Kit Inhibitors for Treating Fibrosis AB SCIENCE 2007-09-27 — — US disclosed
US-20070191267-A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia AB SCIENCE 2007-08-16 — — US disclosed
WO-2007026251-A2 USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA AB SCIENCE (FR) 2007-03-08 — — WO disclosed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 — — US disclosed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225293-A1 Use of C-Kit Inhibitors for Treating Fibrosis KIT, CPA3, CMA1 PYCR1 4197/4885NPSR1 2960/4885MEN1 2998/4885
US-20070249628-A1 Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons KIT, CPA3, CMA1 PYCR1 3916/4885NPSR1 760/4885MEN1 2054/4885
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 PYCR1 4123/4885NPSR1 1666/4885MEN1 1706/4885
US-20070191267-A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia KIT, MAST3, CPA3 PYCR1 2978/4885NPSR1 1314/4885MEN1 2878/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B PYCR1 2570/4885NPSR1 3661/4885MEN1 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback